The Origination Engine

Novel LSE-listed pharmaceutical company focused on pain relief: raising £10m of CLN’s

Novel LSE-listed pharmaceutical company focused on pain relief: raising £10m of CLN’s and/ or equity to meet contractual commitments in UK/ EU and target US dual IPO in next 12~18 months. Expression of interest for £5m CLN paying 10% with terms, warranties/ options to be negotiated, also £1m of equity (already drawn). Strong demand for product – ~£80m of LOIs (diverse) with initial contracts signed and supply underway. $8bn of global opportunity today; projected $50bn by 2027, with high barriers to entry. Extensively licensed by UK Government – GMP, MHRA and Home Office Licencing; early mover in highly regulated market. Listed on London Stock Exchange @ £100m valuation (outperforming AIM All Share index by 33% since IPO)

Club Deal opportunity in Poland for professional investor, to close by YE 2023. Full occupancy yield 15% and IRR 30%+

A group of European investors is looking for one or more professional/ sophisticated co-investor(s) for a very attractive property transaction in Poland whereby an income producing asset (approx. 10% initial yield, 15% on full occupancy) can be bought at a very significant discount to replacement costs. In total there is a gap of approx. EUR 8-10m to be filled. This deal is urgent as the seller needs to get it done before YE, hence the attractive pricing. **STAK does not verify deal credentials you are responsible for your own due diligence, and opportunities are not accessible to retail investors**

£35m funding line available for purchase of Student Accommodation development opportunities in UK

Client is looking for opportunities in the UK to buy student accommodation sites or BTR schemes which are part built, distressed or in administration Large funding line up to £35m to deploy for Developers looking to exit existing finance arrangements that have come to an end

Co-investors sought for Biotech with commercialised infection prevention products for pre-listing funding

**Sophisticated investors only, enquiries via members please** Firm is the only company in the world to have registered a patent on a finished Hypochlorous Acid (HOCL) product, removing the need for alcohol-based sanitising products. They have created a formulation that not only has excellent shelf life but additionally maintains efficacy in the presence of serum (blood, saliva, dirt etc).
Up to £5m capital is currently being raised at a pre-money valuation of £58m (EIS shares and/or (ii) non-EIS convertible debt investment). This represents a 71% discount to the initial listing valuation of >£200m targeted by management at the Company’s planned IPO on the London Stock Exchange. To date >£14m invested in development of licensed technology into commercially viable products that meet an unmet public health need (funds raised via CLN) Two non-alcohol sanitising products already commercial, in active use in NHS. **Sophisticated/ Professional Investors ONLY** **Further details available within, verified members only**

EU regulated fund 10Yr record raised USD500m, 3x returns, requires 3yr bridge at 20% coupon but min 1.3x

The fund has a >10yr track record and has raised approx. USD 500m to-date with robust return prospects for investors (>2-3x). Invests in mining for rare earth minerals in EMEA Ideally bridge for 3yrs at 20% PIK interest but a min of 1.3x. Fund is exposed to mining but their commodities are sought after renewables commodities. Regulated fund with blue chip western investors (endowments, family offices etc.) Ideal investors are UHNW’s and Family Offices.

Invoice Discounter with £1.5bn financed to date, offering simple funding for SME's with 3 day turnaround

*Introducers Welcome* Invoice Discounter with £1.5bn financed to date, offering simple funding for SME's with 3 day turnaround. Selective invoice discounting allows you to forward fund invoices against quality counterparties. Lender has funded invoices for SME's against Pfizer, Apple, Aviva, BUPA and many others across 45 OECD countries. Credit policies will apply. $1.5bn, 120,000 invoices financed, across 1,800 debtors. $50k to $5m funding lines with no PG's, Liens, Debentures. Invoices financed via proprietary technology in GBP/ USD/ CAD/ EUR among others. Process is simple: load confirmed invoice, invoice verified by payer against bank account IN YOUR NAME, invoice paid to you and when payment received you are immediately paid invoice net of fees. This is non-recourse: invoice financier takes the risk.

FCA Regulated Adviser with USD20bn of transactions completed looking to provide clean-up/ liquidity solutions before year-end

It’s the time of the year when investors realize that they might have a need for a clean-up transaction before year end. Adviser can look at anything that needs to be sold/traded/transferred etc. before year end (such as fund interests, claims, property, corporate holdings, etc.). All major currencies considered but typically GBP, USD, EUR, CHF. Could also take positions onto a Family Office’s own book and have an upside sharing agreement with the seller/transferor in cases where the seller/transferor doesn’t want to incur another set of fees if not sold before year end (such as admin or custodian fees, legal, reporting, accounts etc.) but at the same time believes there is more value to it than what can be achieved with an outright sale. *Credentials and examples within* *Subject to contract and due diligence*

Factoring company seeks partner for 10m-50m EU/USD debt line; 10% yield for credit insured blue chip corporate receivables

Established business delivers working capital solutions through a proprietary cloud-based platform that provides non-recourse, flexible, secure and scalable funding to clients. Firm has discounted c. €1.5 billion invoices to date for over 450 clients based in the UK, USA, Canadian and European markets. Model transfers the credit risk from its clients to highest quality buyers/debtors based in circa 45 OECD countries where the receivables are credit insured, verified and payable directly by the buyer/debtor. First level risk covered; institutional grade due diligence and reporting. Require €10-50m debt line paying 10% to facilitate demand, with the aim of funding €2 billion of receivables annually by 2025. **Detailed deck attached within** ***Professional Investors Only*** MINIMUM CRITERIA and CONDITIONS APPLY

Jersey and UK lender seeking direct loan portfolios for outright acquisition/ phased exit or professional management

Opportunity for Jersey private funders, holding direct lending portfolios, to sell or transfer their position in favour of a Schedule 2 registered programme, with diversification, regular coupon of 8% and a partial first loss guarantee, supported with institutional-grade reporting and independently audited by a major practice. Single loans or multi-lend books considered, as well as mildly non-performing or overrunning debt. Typical book size £2m-£10m however smaller/ larger portfolios will be considered by negotiation.